I grant Medpace (NASDAQ: MEDP ) a buy rating. I am of the opinion that there are substantial grounds to believe that the company will continue to generate value for its investors. To begin with, the companyDaniel Mellado is an economist from Carabobo University with a Master's Degree in Statistics from Simon Bolivar University, both obtained in Venezuela.Daniel worked analyzing the agricultural commodity market and the financial investment portfolio for an agribusiness group. Then, he managed two teams, one ...